Lyell Immunopharma’s (LYEL) Buy Rating Reaffirmed at HC Wainwright

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $45.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 265.56% from the stock’s previous close.

A number of other brokerages have also issued reports on LYEL. Needham & Company LLC reissued a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a research note on Monday. Zacks Research raised shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Citigroup reaffirmed a “market outperform” rating on shares of Lyell Immunopharma in a research note on Tuesday. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Finally, Citizens Jmp began coverage on Lyell Immunopharma in a research report on Monday, March 9th. They set a “market outperform” rating and a $34.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.00.

Lyell Immunopharma Trading Up 2.8%

Shares of NASDAQ:LYEL opened at $12.31 on Tuesday. Lyell Immunopharma has a 12 month low of $8.46 and a 12 month high of $45.00. The company has a market cap of $287.24 million, a price-to-earnings ratio of -0.89 and a beta of -0.09. The company has a 50-day moving average price of $19.71 and a 200 day moving average price of $23.43.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%.The firm had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.00 million. As a group, equities analysts forecast that Lyell Immunopharma will post -7.87 EPS for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

A number of large investors have recently bought and sold shares of LYEL. AQR Capital Management LLC raised its stake in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after buying an additional 154,327 shares in the last quarter. Marshall Wace LLP bought a new position in Lyell Immunopharma in the second quarter worth approximately $94,000. Bridgeway Capital Management LLC bought a new position in Lyell Immunopharma in the second quarter worth approximately $159,000. BBR Partners LLC bought a new position in Lyell Immunopharma in the fourth quarter worth approximately $210,000. Finally, Walleye Capital LLC bought a new position in Lyell Immunopharma in the second quarter worth approximately $258,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.